Get started
Author

Margherita Maffioli

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
2009 · Francesco Passamonti, Francisco Cervantes, et al. · Blood · 997
PDF
Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making
2005 · Luca Malcovati, Matteo Giovanni Della Porta, et al. · Journal of Clinical Oncology · 865
PDF
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
2014 · A Tefferi, T L Lasho, et al. · Leukemia · 548
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
2017 · F Passamonti, T Giorgino, et al. · Leukemia · 348
PDF
A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
2012 · Francesco Passamonti, Jürgen Thiele, et al. · Blood · 277
PDF
EZH2 mutational status predicts poor survival in myelofibrosis
2011 · Paola Guglielmelli, Flavia Biamonte, et al. · Blood · 262
PDF
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
2014 · Ayalew Tefferi, Emnet A. Wassie, et al. · American Journal of Hematology · 213
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
2017 · Paola Guglielmelli, Annalisa Pacilli, et al. · Blood · 187
PDF
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
2015 · Nicolaus Kröger, Toni Giorgino, et al. · Blood · 186
PDF
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
2010 · Alejandra Martínez-Trillos, Anna Gaya, et al. · Annals of Hematology · 148
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome
2006 · M G Della Porta, L Malcovati, et al. · Leukemia · 137
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
2022 · Margherita Maffioli, Barbara Mora, et al. · Blood Advances · 128
PDF
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome
2005 · L Malcovati, M G Della Porta, et al. · Leukemia · 125
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
2014 · Francesco Passamonti, Margherita Maffioli, et al. · Blood · 96
PDF
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group
2016 · Giada Rotunno, Annalisa Pacilli, et al. · American Journal of Hematology · 95
PDF
Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project
2014 · Alessandro Maria Vannucchi, Paola Guglielmelli, et al. · Blood · 62
Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases
2014 · Francesco Dentali, Walter Ageno, et al. · Thrombosis Research · 62
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients
2016 · Paola Guglielmelli, Giada Rotunno, et al. · American Journal of Hematology · 60
PDF
Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia
2010 · Margherita Maffioli, Mireia Camós, et al. · Leukemia Research · 58
Update from the latest WHO classification of MPNs: a user’s manual
2016 · Francesco Passamonti, Margherita Maffioli · Hematology · 56
PDF
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
2011 · Francesco Passamonti, Margherita Maffioli, et al. · Oncotarget · 56
PDF
The role of JAK2 inhibitors in MPNs 7 years after approval
2018 · Francesco Passamonti, Margherita Maffioli · Blood · 54
PDF
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients
2016 · F Passamonti, B Mora, et al. · Leukemia · 46
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history
2014 · Naseema Gangat, Emnet A. Wassie, et al. · European Journal Of Haematology · 45
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
2024 · Paola Guglielmelli, Barbara Mora, et al. · American Journal of Hematology · 39
PDF
Works count: 131
Citation count: 6,023
H-index: 28
I10-index: 62
Year
Topic
Type